Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium

insitro Appoints Joe Hand as Chief People Officer to Advance Talent Strategy for Next Stage of Development

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects

Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile

ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer

insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer

Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

Industry Veteran Jonathan Freeman, Ph.D. Joins ARTBIO As Chief Business Officer

Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th

Marea Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics Appoints Sung Lee to Board of Directors

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

Seaport Therapeutics Presents Data Further Validating GlyphTM Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BAMF Health Doses First Patient in Promising New Prostate Cancer Alpha Radioligand Therapy Clinical Trial

Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update